MedTrace Logo

Mineralocorticoid Use in COVID-19 Patients

NCT05453214 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-12

No results posted yet for this study

Summary

There is a considerable variability in aldosterone levels between individuals, and this may explain the wide variability in disease severity among those infected so we designed a pilot study to test for the safety and efficacy of fludrocortisone addition to standard of care in hospitalised COVID-19 patients.

Conditions

Interventions

DRUG

Fludrocortisone Acetate 0.1 MG

Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Muhammad S Zeafan · Alazhar allergy and immunology center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-04
Primary Completion
2022-03-03
Completion
2022-06-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453214 on ClinicalTrials.gov